Compare · CAI vs ILMN
CAI vs ILMN
Side-by-side comparison of Caris Life Sciences Inc. (CAI) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAI and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $29.37B, about 30.2x CAI ($971.9M).
- Over the past year, CAI is down 42.6% and ILMN is up 76.5% - ILMN leads by 119.1 points.
- Both names hit the wire about 3 times in the past 4 weeks.
- ILMN has more recent analyst coverage (25 ratings vs 15 for CAI).
- Company
- Caris Life Sciences Inc.
- Illumina Inc.
- Price
- $15.53-0.80%
- $194.06-1.49%
- Market cap
- $971.9M
- $29.37B
- 1M return
- -14.41%
- +10.86%
- 1Y return
- -42.59%
- +76.55%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 3
- 3
- Recent ratings
- 15
- 25
Caris Life Sciences Inc.
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CAI
- Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
- Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
- Director Halbert Jon bought $990,080 worth of shares (68,000 units at $14.56) (SEC Form 4)
- Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test
- SEC Form CERT filed by Caris Life Sciences Inc.
- SEC Form 8-A12B filed by Caris Life Sciences Inc.
- Caris Life Sciences Announces Dual Listing on NYSE Texas
- Caris Life Sciences Announces Share Repurchase Program
- Caris Life Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Poste George was granted 1,600 shares, increasing direct ownership by 10% to 17,729 units (SEC Form 4)
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits